For separate model simulations of JAK2 subgroups, the incidences of MF and thrombosis reached considerably higher levels for patients with JAK2 >50%, which might imply that possible differences in JAK2 levels across different studies could explain differences in incidence of MF and thrombosis. This evidence concerns the gene JAK2 and deep vein thrombosis.